Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
NCT02772783 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2021-06-18
Summary
Processed carbohydrates cause rapid changes in blood sugar and have been associated with overeating and obesity. We have shown that test meals high in processed carbohydrate affect brain areas involved in addiction, craving and overeating. It is unknown whether the changes in blood sugar or the associated higher insulin levels mediate this brain activation and its likely adverse effects.
Answering this question is important for patients with type 1 diabetes who have elevated risks of obesity and disordered eating: If blood sugar is the causal mechanism, optimal insulin coverage should be protective. If insulin is the causal mechanism, however, a diet high in processed carbohydrate could predispose to overeating and weight gain, as this diet requires higher insulin doses.
To disentangle these factors, we will study brain activation and relevant blood markers in 15 men with diabetes. In 4 sessions, we will examine meals with differential carbohydrate properties while giving insulin infusions.
Conditions
- Diabetes Mellitus, Type 1
Interventions
- OTHER
-
high GI meal
High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
- OTHER
-
low GI meal
High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
- DRUG
-
euglycemic insulin clamp
Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
- DRUG
-
primed-variable insulin infusion
A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
Sponsors & Collaborators
-
Beth Israel Deaconess Medical Center
collaborator OTHER -
Brigham and Women's Hospital
collaborator OTHER - lead OTHER
Principal Investigators
-
Belinda S Lennerz, MD, PhD · Boston Children's Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2018-05-31
- Completion
- 2018-05-31
Countries
- United States
Study Locations
More Related Trials
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 ·Status: COMPLETED ·Phase: NA
-
Eating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy
NCT07151924 ·Status: ACTIVE_NOT_RECRUITING
-
Lifestyle Control of Postprandial Hyperglycemia
NCT02683135 ·Status: COMPLETED ·Phase: NA
-
Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults
NCT04730882 ·Status: COMPLETED
-
To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.
NCT03414333 ·Status: COMPLETED ·Phase: NA
-
Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes
NCT03392441 ·Status: COMPLETED ·Phase: NA
-
Effects of Age and Obesity on Brain Insulin Sensitivity
NCT04372849 ·Status: COMPLETED ·Phase: NA
-
Improving Insulin Sensitivity by Non-invasive Brain Stimulation
NCT04420650 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men
NCT00256256 ·Status: COMPLETED ·Phase: NA
-
Relative Contribution of Brain Insulin Action for Postprandial Metabolism
NCT06295640 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
NCT01206322 ·Status: COMPLETED ·Phase: PHASE2
-
Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes
NCT01977833 ·Status: UNKNOWN ·Phase: NA
-
Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge
NCT03061227 ·Status: COMPLETED ·Phase: NA
-
Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet
NCT05536232 ·Status: UNKNOWN ·Phase: NA
-
Effects of Oral vs Intravenous Glucose Administration on Novel Candidates of Energy Regulation
NCT04888325 ·Status: COMPLETED ·Phase: NA
-
Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet
NCT03710928 ·Status: RECRUITING ·Phase: NA
-
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740 ·Status: UNKNOWN ·Phase: NA
-
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
NCT07313384 ·Status: RECRUITING
-
Low Glycemic Index Diet in Patients With Type 1 Diabetes
NCT01184703 ·Status: COMPLETED ·Phase: PHASE3
-
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
NCT01592279 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832 ·Status: RECRUITING ·Phase: NA
-
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
NCT04506216 ·Status: COMPLETED ·Phase: NA
-
Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)
NCT06144255 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
NCT03383822 ·Status: COMPLETED ·Phase: PHASE1/PHASE2